For clinicians and patients navigating colonoscopy surveillance decisions after age 75, a striking set of numbers is reshaping the calculus: a prior adenoma finding may matter far less than long assumed when competing causes of death dominate the mortality landscape. This reframing has immediate implications for reducing procedural burden in elderly populations — but the caveats embedded in new correspondence deserve careful scrutiny before surveillance protocols are loosened broadly.
The figures under discussion emerge from a cohort study reporting that adults aged 75 or older with a prior adenoma faced a 10-year cumulative colorectal cancer incidence of just 1.1%, with colorectal cancer–specific mortality at 0.5%. By contrast, non-colorectal cancer mortality in the same group approached 50%. The absolute excess risk attributable to adenoma history was therefore narrow, prompting serious questions about whether intensified colonoscopic surveillance in this age band delivers meaningful survival benefit relative to procedural risk and patient burden. Correspondence published in JAMA raises two methodological concerns about translating these findings into sweeping deimplementation of surveillance guidelines.
This finding sits within a maturing evidence base questioning routine surveillance colonoscopy in older adults. The NordICC trial and U.S. Preventive Services Task Force guidance have already nudged the field toward age-stratified risk-benefit thinking. The adenoma-to-carcinoma progression timeline — typically 10 to 15 years — means that in a 75-year-old, even a detected lesion may never become clinically significant. However, the correspondence flags issues likely involving selection bias or adenoma subtype heterogeneity, reminding readers that aggregate statistics mask variation: high-risk adenoma features (large size, villous histology, high-grade dysplasia) may still confer meaningful individual risk regardless of age. This appears to be an incrementally important, rather than paradigm-shifting, contribution — most valuable as evidence supporting shared decision-making conversations rather than a mandate for blanket surveillance cessation in all adults over 75.